Login / Signup

Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors.

Hua GuoQingqing DingYun GongMichael Z GilcreaseMin ZhaoJun ZhaoDawen SuiYun WuHui ChenHui LiuJinxia ZhangErika ResetkovaStacy L MoulderWei-Lien WangLei Huo
Published in: Breast cancer research : BCR (2020)
Our findings indicate that the three scoring methods with a 1% cutoff are different in their sensitivity for PD-L1 expression and their associations with clinicopathologic factors. Scoring by TCIC is the most sensitive way to identify PD-L1-positive breast cancer by immunohistochemistry. As a prognostic marker, our study suggests that PD-L1 is associated with worse clinical outcome, most often shown by the IC score; however, the other scores may also have clinical implications in some subgroups. Large clinical trials are needed to test the similarities and differences of these scoring methods for their predictive values in anti-PD-1/PD-L1 therapy.
Keyphrases
  • positive breast cancer
  • clinical trial
  • high throughput
  • stem cells
  • randomized controlled trial
  • mesenchymal stem cells